Studieoverzicht

 
 
 
  2018-03 TRAIN-3       Submitted (METC)       Neoadjuvant       HER2+, any HR       Not applicable  
  2017-05 SELECT       Open       Locoregional       Not applicable       Both pre- and postmenopausal  
  2017-04 BYLieve       Open       Neoadjuvant       HER2- HR+       Not applicable  
  2017-03 SONIA       Open       Advanced/metastatic       HER2- HR+       Not applicable  
  2017-02 PERIDENO       Closed       Adjuvant       HER2-, any HR       Postmenopausal  
  2017-01 NEOLBC       Open       Neoadjuvant       HER2- HR+       Postmenopausal  
  2016-03 PRECISE       Open       Adjuvant       Not applicable       Not applicable  
  2016-02 PALLAS       Open       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2016-01 TOP-1       Open       Data registration       HER2- HR+       Postmenopausal  
  2015-03 POSITIVE       Open       Adjuvant       Any HER2, HR+       Premenopausal  
  2015-02 MonaLEEsa-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2015-01 Monarch-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2014-05 INFLAME       Open       Data registration       Not applicable       Not applicable  
  2014-04 LORD       Open       Locoregional       Not applicable       Both pre- and postmenopausal  
  2014-03 OLYMPIA       Open       Adjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2014-02 BRAVO       Follow up       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2014-01 MONALEESA-2       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-08 lumpectomie       Open       Locoregional       Not applicable       Not applicable  
  2013-07 mastectomie       Follow up       Locoregional       Not applicable       Not applicable  
  2013-06 Biomarker Study Everolimus       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-05 BELLE-3       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2013-04 DIRECT       Follow up       Neoadjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2013-03 PERNETTA       Follow up       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2013-02 Male BC prospectief       Follow up       Data registration       Not applicable       Not applicable  
  2013-01 Triple-B       Open       Advanced/metastatic       TNBC       Both pre- and postmenopausal  
  2012-03 TRAIN-2       Follow up       Neoadjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2012-02 SafeHer       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2012-01 BALLET       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2011-02 APHINITY       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2011-01 Abiraterone       Follow up       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2010-05 SUBMIT       Closed       Advanced/metastatic       Any HER2, any HR       Both pre- and postmenopausal  
  2010-04 D-Care       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2010-03 RAPCHEM       Follow up       Locoregional       Not applicable       Not applicable  
  2010-02 STOP&GO       Follow up       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2010-01 NEO-ZOTAC       Follow up       Neoadjuvant       HER2-, any HR       Both pre- and postmenopausal  
  2009-05 BOLERO 2       Closed       Advanced/metastatic       HER2- HR+       Postmenopausal  
  2009-04 Male BC retrospectief       Closed       Data registration       Not applicable       Not applicable  
  2009-03 DCIS       Follow up       Locoregional       Not applicable       Not applicable  
  2009-02 SNARB       Closed       Locoregional       Not applicable       Not applicable  
  2009-01 IRMA       Follow up       Locoregional       Not applicable       Not applicable  
  2008-03 HAT       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2008-02 A6181099       Closed       Advanced/metastatic       Any HER2, any HR       Both pre- and postmenopausal  
  2008-01 2-2-6 G-CSF       Closed       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2007-02 INTENS       Closed       Neoadjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2007-01 ALTTO       Follow up       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2006-07 MIRROR       Closed       Not applicable       Not applicable       Not applicable  
  2006-06 ATX       Closed       Advanced/metastatic       HER2-, any HR       Both pre- and postmenopausal  
  2006-05 IDEAL       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-04b TEAM IIb       Closed       Adjuvant       Any HER2, HR+       Postmenopausal  
  2006-04a TEAM IIa       Closed       Neoadjuvant       Any HER2, HR+       Postmenopausal  
  2006-03 SUPREMO       Follow up       Locoregional       Not applicable       Not applicable  
  2006-02 OMEGA       Closed       Advanced/metastatic       Any HER2, any HR       Postmenopausal  
  2006-01 DATA       Follow up       Adjuvant       Any HER2, HR+       Postmenopausal  
  2005-03 MINDACT       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2005-02 MATADOR       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2004-02 TBP       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2004-01 Young Boost       Follow up       Locoregional       Not applicable       Not applicable  
  2003-04 Pregnancy       Follow up       Not applicable       Any HER2, any HR       Premenopausal  
  2003-02 Calor       Follow up       Adjuvant       Any HER2, any HR       Both pre- and postmenopausal  
  2002-04 HERA       Closed       Adjuvant       HER2+, any HR       Both pre- and postmenopausal  
  2002-02 Hertax       Closed       Advanced/metastatic       HER2+, any HR       Both pre- and postmenopausal  
  2001-02 AMAROS       Closed       Locoregional       Not applicable       Not applicable  
  2001-01 TEAM       Closed       Adjuvant       Any HER2, HR+       Postmenopausal